Coronavirus Update: Moderna Shows 100% Efficacy In Teens
Plus, J&J's Vaccine Filed In Japan, Korea, India Supply Developments
Moderna's mRNA-1273 vaccine prevented significant illness after two doses in all patients in the TeenCOVE trial, ages 12-18. The company will submit the data to global regulators in June. Meanwhile, J&J has applied for the Japanese approval of its vaccine, Moderna progresses plans in Korea, and India plans to ramp up vaccine supplies.
